Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)

NCT07200739 · tracked via the Priya Life Science Denmark tracker
Phase
Observational
Started
2026-11-01
Last updated
2026-09-02

Condition(s) studied

Dementia (Diagnosis)Alzheimer Dementia (AD)Vascular Dementia (VaD)Lewy Body Dementia (LBD)Frontotemporal Dementia (FTD)Mild Cognitive Impairment (MCI)Depression - Major Depressive DisorderStressCognitive Impairment

Investigational drug(s) / intervention(s)

Mini-mental State ExaminationAddenbrooke's Cognitive ExaminationSpeech Task - Picture DescriptionSpeech Task - Picture RecallMRIblood samplingDepression screeningSomatic- and neurological examinationSpeech Task - Picture Narrative

Mini-mental State Examination: Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.

Addenbrooke's Cognitive Examination: Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.

Speech Task - Picture Description: Participants will be asked to describe the Cookie Theft Picture from the Boston Diagnostic Aphasia Examination. The task will take 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns.

Speech Task - Picture Recall: Participants will be asked to recall the picture shown in the previous speech task "Picture Narrative". This task will take 2 minutes. Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.

MRI: For healthy controls an MRI will be conducted to provide comparable imaging and as part of screening to ensure they do not meet exclusion criteria (neuroradiological findings that could affect cognitive functions). For patient participants, imaging will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal.

blood sampling: Healthy control participants will undergo a standard blood test panel commonly used in dementia diagnostics. The panel includes complete blood counts, inflammatory markers, kidney- and liver function markers, thyroid-stimulating hormone (TSH), vitamine B12 and folate. These tests are performed to exclude underlying medical conditions that could mimic cognitive impairment. For patient participants, blood sampling will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal.

Depression screening: Performed on healthy controls to rule out depression using either the geriatric depression scale (GDS) for patients \> 65 year of age or the Major Depression Index (MDI) for patiens \<65 year of age. For patient participants, depression screening will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal.

Somatic- and neurological examination: Healthy controls will undergo a standard somatic and neurological examination to exclude conditions that may affect cognition. This includes basic neurological assessment and clinical evaluation of general health status. For patient participants, a somatic and neurological examination will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal

Speech Task - Picture Narrative: The participant is asked to tell a brief story based on a culturally neutral picture. This task will take approximately 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns

Study summary

The goal of this observational study is to learn if an artificial intelligence (AI)-based speech analysis tool can identify which patients with memory problems need specialist evaluation at a memory clinic. The main questions it aims to answer are:

Can the AI model accurately distinguish between patients who need referral to a memory clinic (those with dementia or Mild Cognitive Impairment) and patients who don't (those with normal cognition or memory problems from other causes like depression)? Which speech patterns and cognitive test features are most useful for making this distinction?

Researchers will compare speech recordings and cognitive test results from patients diagnosed with dementia or MCI to those from patients with normal cognition or non-neurodegenerative cognitive impairment to see if the AI model can reliably predict who needs specialist dementia care.

Participants will:

Complete standard cognitive tests at the memory clinic Perform structured speech tasks while being audio-recorded Receive their usual clinical evaluation and diagnosis from memory clinic specialists

The results of this study will help develop a tool that can assist doctors in making faster, more accurate decisions about which patients need specialist dementia evaluation, potentially leading to earlier diagnosis and better patient outcomes.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Model A (patient participants) * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling * A diagnosis of either MCI or AD, given at the SUH memory clinic within 6 months before enrollment Model A (cognitively healthy controls) * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling Model B: * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling Exclusion Criteria: Model A: Patients: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE score \< 16 * Concomitant diagnoses which are expected to influence cognitive impairment (eg. depression) * Patients unable to give consent * Patients with alcohol consumption \>21 standard alcohol units per week * Any history of speech or language impairment predating the current condition Cognitively healthy controls: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE \< 26 and ACE \< 90 * Clinical, laboratory, or neuroradiological findings that could affect cognitive functions * Known diseases which are expected to impair cognitive functions * Any history of speech or language impairment predating the current condition * Patients with alcohol consumption \>21 standard alcohol units per week. Model B: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE score \< 16 * Patients unable to give consent * Patients with concomitant psychosis or severe psychiatric comorbidities other than depression * Any history of speech or language impairment predating the current condition

Primary outcome measure(s)

  • Model A: Primary measure is the AUC-ROC of the model in distinguishing between MCI and AD as well as between MCI and cognitively healthy control participants. — At baseline (speech recording)
    We will measure the AUR-ROC of AI predictions compared to clinical consensus diagnosis. Metrics will be presented including uncertainty estimates. Model performance will be measured on an independent test-set consisting of patients from the model B training population.

Trial sites (1)

FacilityCityRegionStatus
Zealand University Hospital Roskilde Region Sjælland
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07200739 on ClinicalTrials.gov ↗ ← All trials in Denmark